{"id":"sodium-polystyrene-sulfonate","rwe":[],"_fda":{"id":"929068a8-cf62-468b-bc5c-b311d6b37f07","set_id":"03a0b525-5e48-4e76-b1fa-700eab10d20a","openfda":{"nui":["N0000178378","N0000175357"],"unii":["1699G8679Z"],"route":["ORAL","RECTAL"],"rxcui":["2101899"],"spl_id":["929068a8-cf62-468b-bc5c-b311d6b37f07"],"brand_name":["SODIUM POLYSTYRENE SULFONATE"],"spl_set_id":["03a0b525-5e48-4e76-b1fa-700eab10d20a"],"package_ndc":["63629-2390-1"],"product_ndc":["63629-2390"],"generic_name":["SODIUM POLYSTYRENE SULFONATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["SODIUM POLYSTYRENE SULFONATE"],"pharm_class_epc":["Potassium Binder [EPC]"],"pharm_class_moa":["Potassium Ion Exchange Activity [MoA]"],"manufacturer_name":["Bryant Ranch Prepack"],"application_number":["ANDA204071"],"original_packager_product_ndc":["11534-166"]},"version":"104","overdosage":["10 OVERDOSAGE Overdosage may result in electrolyte disturbances including hypokalemia, hypocalcemia, and hypomagnesemia. Appropriate measures should be taken to correct serum electrolytes (potassium, calcium, magnesium), and the resin should be removed from the alimentary tract by appropriate use of laxatives or enemas."],"description":["11 DESCRIPTION Sodium polystyrene sulfonate is a benzene, diethenyl- polymer, with ethenylbenzene, sulfonated, sodium salt and has the following structural formula: n The drug is a golden brown finely ground, powdered form of sodium polystyrene sulfonate, a cation-exchange resin prepared in the sodium phase with an in vitro exchange capacity of approximately 3.1 mEq ( in vivo approximately 1 mEq) of potassium per gram. The sodium content is approximately 100 mg (4.1 mEq) per gram of the drug. It can be administered orally or in an enema. One gram of sodium polystyrene sulfonate contains 4.1 mEq of sodium."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Sodium polystyrene sulfonate for suspension is available as a golden brown, finely ground powder in jars of 1 pound (454 g), NDC 63629-2390-1. Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature] Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504"],"effective_time":"20240412","adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere in the labeling: Intestinal Necrosis [see Warnings and Precautions (5.1) ] Electrolyte Disturbances [see Warnings and Precautions (5.2, 5.3) ] Aspiration [see Warnings and Precautions (5.4) ] The following adverse reactions have been identified during post-approval use of sodium polystyrene sulfonate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure. Gastrointestinal : anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, ulcerations, vomiting, gastric irritation, intestinal obstruction (due to concentration of aluminium hydroxide) Metabolic : systemic alkalosis Adverse reactions reported include: anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, vomiting ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Sunrise Pharmaceutical Inc. at 1-732-382-6085 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ."],"contraindications":["4 CONTRAINDICATIONS Sodium polystyrene sulfonate is contraindicated in patients with the following conditions: Hypersensitivity to polystyrene sulfonate resins Obstructive bowel disease Neonates with reduced gut motility Hypersensitivity to polystyrene sulfonate resins ( 4 ) Obstructive bowel disease ( 4 ) Neonates with reduced gut motility ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Take other orally administered drugs at least 3 hours before or 3 hours after sodium polystyrene sulfonate ( 7.1 ). Cation-Donating Antacids: may reduce the resin’s potassium exchange capability and increase risk of systemic alkalosis ( 7.2 ). Sorbitol: Concomitant use may contribute to the risk of intestinal necrosis and is not recommended ( 7.3 ). 7.1 General Interactions No formal drug interaction studies have been conducted in humans. Sodium polystyrene sulfonate has the potential to bind other drugs. In in vitro binding studies, sodium polystyrene sulfonate was shown to significantly bind the oral medications (n=6) that were tested. Decreased absorption of lithium and thyroxine have also been reported with co-administration of sodium polystyrene sulfonate. Binding of sodium polystyrene sulfonate to other oral medications could cause decreased gastrointestinal absorption and loss of efficacy when taken close to the time sodium polystyrene sulfonate is administered. Administer sodium polystyrene sulfonate at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation. Monitor for clinical response and/or blood levels where possible. 7.2 Cation-Donating Antacids The simultaneous oral administration of sodium polystyrene sulfonate with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis. 7.3 Sorbitol Sorbitol may contribute to the risk of intestinal necrosis [ see Warnings and Precautions (5.1) ] and concomitant use is not recommended."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Sodium polystyrene sulfonate is a non-absorbed, cation exchange polymer that contains a sodium counterion. Sodium polystyrene sulfonate increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels. The practical exchange ratio is 1 mEq K per 1 gram of resin. As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. This action occurs primarily in the large intestine, which excretes potassium ions to a greater degree than does the small intestine. The efficiency of this process is limited and unpredictably variable. 12.2 Pharmacodynamics The effective lowering of serum potassium with sodium polystyrene sulfonate may take hours to days. 12.3 Pharmacokinetics The in vivo efficiency of sodium-potassium exchange resins is approximately 33 percent; hence, about one third of the resin's actual sodium content is delivered to the body. Sodium polystyrene sulfonate is not absorbed systemically. Drug Interactions In vitro binding studies showed that sodium polystyrene sulfonate bound significantly to the following tested drugs – warfarin, metoprolol, phenytoin, furosemide, amlodipine and amoxicillin."],"indications_and_usage":["1 INDICATIONS AND USAGE Sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. Limitation of Use : Sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) ] Sodium polystyrene sulfonate for suspension is a potassium binder indicated for the treatment of hyperkalemia ( 1 ). Limitation of Use : Sodium polystyrene sulfonate for suspension should not be used an emergency treatment for life threatening hyperkalemia because of its delayed onset of action ( 1 )."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Intestinal Necrosis : cases of intestinal necrosis and other serious gastrointestinal events have been reported ( 5.1 ). Electrolyte Disturbances : Severe hypokalemia can occur. ( 5.2 ). Fluid overload in patient sensitive to high sodium intake : Monitor patients who are sensitive to sodium intake for signs of fluid overload. ( 5.3 ). Risk of aspiration : Acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles has been reported. ( 5.4 ). 5.1 Intestinal Necrosis Cases of intestinal necrosis, some fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with sodium polystyrene sulfonate use. The majority of these cases reported the concomitant use of sorbitol. Risk factors for gastrointestinal adverse events were present in many of the cases including prematurity, history of intestinal disease or surgery, hypovolemia, and renal insufficiency and failure. Concomitant administration of sorbitol is not recommended. Use only in patients who have normal bowel function. Avoid use in patients who have not had a bowel movement post-surgery. Avoid use in patients who are at risk for developing constipation or impaction (including those with history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction). Discontinue use in patients who develop constipation. 5.2 Electrolyte Disturbances Monitor serum potassium during therapy because severe hypokalemia may occur. Sodium polystyrene sulfonate is not totally selective for potassium, and small amounts of other cations such as magnesium and calcium can also be lost during treatment. Monitor calcium and magnesium in patients receiving sodium polystyrene sulfonate. 5.3 Fluid Overload in Patients Sensitive to High Sodium Intake Each 15 g dose of sodium polystyrene sulfonate contains 1500 mg (60 mEq) of sodium. Monitor patients who are sensitive to sodium intake (heart failure, hypertension, edema) for signs of fluid overload. Adjustment of other sources of sodium may be required. 5.4 Risk of Aspiration Cases of acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles have been reported. Patients with impaired gag reflex, altered level of consciousness, or patients prone to regurgitation may be at increased risk. Administer sodium polystyrene sulfonate with the patient in an upright position. 5.5 Binding to Other Orally Administered Medications Sodium polystyrene sulfonate may bind orally administered medications, which could decrease their gastrointestinal absorption and lead to reduced efficacy. Administer other oral medications at least 3 hours before or 3 hours after sodium polystyrene sulfonate. Patients with gastroparesis may require a 6 hour separation. [see Dosage and Administration (2.1) and Drug Interactions (7) ]."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Drug Interactions Advise patients who are taking other oral medication to separate the dosing of sodium polystyrene sulfonate by at least 3 hours (before or after) [ see Dosage and Administration (2.1) , Warnings and Precautions (5.5) , and Drug Interactions (7.1) ] Rx Only Manufactured & Distributed by: Sunrise Pharmaceutical, Inc. Rahway, NJ 07065 Revised March 2020 5082/06"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Oral : The average total daily adult dose of sodium polystyrene sulfonate is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily ( 2.1 ). Rectal : The average adult dose is 30 g to 50 g every six hours ( 2.1 ). 2.1 General Information Administer sodium polystyrene sulfonate at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation [see Warnings and Precautions(5.5 ) and Drug Interaction(7) ] 2.2 Recommended Dosage The intensity and duration of therapy depend upon the severity and resistance of hyperkalemia. Oral The average total daily adult dose of sodium polystyrene sulfonate is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily. Rectal The average adult dose is 30 g to 50 g every six hours. 2.3 Preparation and Administration Prepare suspension fresh and use within 24 hours. Do not heat sodium polystyrene sulfonate as it could alter the exchange properties of the resin. One level teaspoon contains approximately 3.5 g of sodium polystyrene sulfonate and 15 mEq of sodium. Oral Suspension Suspend each dose in a small quantity of water or syrup, approximately 3 to 4 mL of liquid per gram of resin. Administer with patient in an upright position [see Warnings and Precautions (5.4) ]. Enema After an initial cleansing enema, insert a soft, large size (French 28) rubber tube into the rectum for a distance of about 20 cm, with the tip well into the sigmoid colon, and tape in place. Administer as a warm (body temperature) emulsion in 100 mL of aqueous vehicle and flush with 50 to 100 ml of fluid. A somewhat thicker suspension may be used, but do not form a paste. Agitate the emulsion gently during administration. The resin should be retained for as long as possible and follow by a cleansing enema with a nonsodium containing solution. Ensure an adequate volume of cleansing solution (up to 2 liters) is utilized."],"spl_product_data_elements":["SODIUM POLYSTYRENE SULFONATE sodium polystyrene sulfonate SODIUM POLYSTYRENE SULFONATE POLYSTYRENE SULFONIC ACID SODIUM CATION GOLDEN image description"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Sodium polystyrene sulfonate for suspension is a golden brown, finely ground powder and is available in 454 g jars and 15 g bottles. Sodium polystyrene sulfonate for suspension is available as a golden brown, finely ground powder ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. 8.2 Lactation Risk Summary Sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. 8.4 Pediatric Use Studies of safety and efficacy have not been conducted in pediatric patients. In pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the practical exchange ratio of 1mEq potassium per 1 gram of resin. In neonates, sodium polystyrene sulfonate should not be given by the oral route. In both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. Premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with sodium polystyrene sulfonate use [ see Warnings and Precautions (5.4) ]."],"package_label_principal_display_panel":["Sodium Polystyrene Sulfonate Powder, #454 Label"]},"tags":[{"label":"Potassium Binder","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"V03AE01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Powder","category":"form"},{"label":"Suspension","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Hyperkalemia","category":"indication"},{"label":"Concordia","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Cation Exchange Resins","category":"pharmacology"},{"label":"Chelating Agents","category":"pharmacology"},{"label":"Ion Exchange Resins","category":"pharmacology"},{"label":"Sequestering Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"HYPERKALAEMIA","source":"FDA FAERS","actionTaken":"109 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"105 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"99 reports"},{"date":"","signal":"RENAL FAILURE","source":"FDA FAERS","actionTaken":"95 reports"},{"date":"","signal":"CONSTIPATION","source":"FDA FAERS","actionTaken":"94 reports"},{"date":"","signal":"CHRONIC KIDNEY DISEASE","source":"FDA FAERS","actionTaken":"91 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"82 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"73 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"66 reports"},{"date":"","signal":"END STAGE RENAL DISEASE","source":"FDA FAERS","actionTaken":"65 reports"}],"commonSideEffects":[{"effect":"Fecal impaction","drugRate":"reported","severity":"unknown"},{"effect":"Gastrointestinal concretions (bezoars)","drugRate":"reported","severity":"unknown"},{"effect":"Ischemic colitis","drugRate":"reported","severity":"unknown"},{"effect":"Gastrointestinal tract ulceration or necrosis","drugRate":"reported","severity":"unknown"},{"effect":"Intestinal perforation","drugRate":"reported","severity":"unknown"},{"effect":"Acute bronchitis","drugRate":"reported","severity":"unknown"},{"effect":"Broncho-pneumonia","drugRate":"reported","severity":"unknown"},{"effect":"Nausea","drugRate":"reported","severity":"unknown"},{"effect":"Vomiting","drugRate":"reported","severity":"unknown"},{"effect":"Constipation","drugRate":"reported","severity":"unknown"},{"effect":"Diarrhea","drugRate":"reported","severity":"unknown"},{"effect":"Hypokalemia","drugRate":"reported","severity":"unknown"},{"effect":"Hypocalcemia","drugRate":"reported","severity":"unknown"},{"effect":"Hypomagnesemia","drugRate":"reported","severity":"unknown"},{"effect":"Sodium retention","drugRate":"reported","severity":"unknown"},{"effect":"Anorexia","drugRate":"reported","severity":"unknown"},{"effect":"Intestinal necrosis","drugRate":"reported","severity":"unknown"},{"effect":"Intestinal obstruction","drugRate":"reported","severity":"unknown"},{"effect":"Gastrointestinal tract necrosis","drugRate":"reported","severity":"unknown"},{"effect":"Gastrointestinal tract irritation","drugRate":"reported","severity":"unknown"},{"effect":"Gastrointestinal tract inflammation","drugRate":"reported","severity":"unknown"}],"contraindications":["Alkalosis","Bowel sounds absent","Chronic heart failure","Chronic idiopathic constipation","Colonic Necrosis","Conduction disorder of the heart","Edema","Fecal impaction","Gastrointestinal hemorrhage","Gastrointestinal hypomotility","Gastrointestinal obstruction","Hypertensive urgency","Hypocalcemia","Hypokalemia","Hypomagnesemia","Hypovolemia","Inflammatory bowel disease","Intestinal obstruction","Ischemic colitis","Kidney disease","Operation on gastrointestinal tract","Prolonged QT interval"],"specialPopulations":{"Pregnancy":"Sodium polystyrene sulfonate should be given to pregnant woman only if clearly needed. Animal reproduction studies have not been conducted with sodium polystyrene sulfonate. It is also not known whether sodium polystyrene sulfonate can cause fetal harm when administered to pregnant woman or can affect reproduction capacity.","Paediatric use":"The effectiveness of sodium polystyrene sulfonate in pediatric patients has not been established. In neonates, sodium polystyrene sulfonate should not be given by the oral route. In both children and neonates particular care should be observed with rectal administration, as excessive dosage or inadequate dilution could result in impaction of the resin. Due to the risk of digestive hemorrhage or intestinal necrosis, particular care should be observed in premature infants or low birth weight infants."}},"trials":[],"aliases":[],"company":"Concordia","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SODIUM POLYSTYRENE SULFONATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:23:48.210254+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:23:54.962858+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:23:46.820767+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SODIUM POLYSTYRENE SULFONATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:23:55.733719+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:23:45.493959+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:23:45.494001+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:23:45.494012+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:23:57.839604+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Potassium sequestering agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:23:56.864789+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201484/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:23:56.737665+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA204071","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:23:45.494023+00:00"}},"allNames":"sps","offLabel":[],"synonyms":["kayexalate","sodium polystyrene sulfonate","sodium p-styrenesulfonate homopolymer"],"timeline":[{"date":"1958-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from CONCORDIA PHARMS INC to Concordia"},{"date":"1958-06-05","type":"positive","source":"DrugCentral","milestone":"FDA approval (Concordia Pharms Inc)"},{"date":"2015-04-03","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 11 manufacturers approved"}],"aiSummary":"Sodium Polystyrene Sulfonate (Sps) is a potassium binder originally developed by Concordia Pharms Inc and currently owned by Concordia. It is a small molecule drug that works by exchanging sodium ions for potassium ions in the gastrointestinal tract, thereby reducing potassium levels in the blood. Sps is approved to treat hyperkalemia and is available as a generic medication, with 14 generic manufacturers. It was first approved by the FDA in 1958 and is no longer patented. As a potassium binder, Sps is a critical medication for managing high potassium levels in patients with kidney disease or other conditions.","approvals":[{"date":"1958-06-05","orphan":false,"company":"CONCORDIA PHARMS INC","regulator":"FDA"}],"brandName":"Sps","ecosystem":[{"indication":"Hyperkalemia","otherDrugs":[{"name":"calcium acetate","slug":"calcium-acetate","company":"B Braun"},{"name":"calcium chloride","slug":"calcium-chloride","company":"Baxter Hlthcare"},{"name":"calcium glucoheptonate","slug":"calcium-glucoheptonate","company":"Abbott"},{"name":"calcium glycerylphosphate","slug":"calcium-glycerylphosphate","company":""}],"globalPrevalence":null}],"mechanism":{"novelty":"First-in-class","moaClass":"Potassium Ion Exchange Activity","modality":"Small Molecule","drugClass":"Potassium Binder [EPC]","explanation":"","oneSentence":"","technicalDetail":"Sps is a cation exchange resin that selectively binds to potassium ions in the gastrointestinal tract, facilitating their excretion and reducing serum potassium levels."},"commercial":{"launchDate":"1958","_launchSource":"DrugCentral (FDA 1958-06-05, CONCORDIA PHARMS INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4487","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=SODIUM%20POLYSTYRENE%20SULFONATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SODIUM POLYSTYRENE SULFONATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:39:34.422865","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:24:01.904489+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"sevelamer","drugSlug":"sevelamer","fdaApproval":"1998-10-30","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"lanthanum carbonate","drugSlug":"lanthanum-carbonate","fdaApproval":"2004-10-26","patentExpiry":"Dec 1, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"sucroferric oxyhydroxide","drugSlug":"sucroferric-oxyhydroxide","fdaApproval":"2013-11-27","relationship":"same-class"},{"drugName":"calcium acetate","drugSlug":"calcium-acetate","fdaApproval":"1982-05-06","patentExpiry":"Jul 20, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ferric citrate","drugSlug":"ferric-citrate","fdaApproval":"2014-09-05","patentExpiry":"Jul 21, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"patiromer calcium","drugSlug":"patiromer-calcium","fdaApproval":"2015-10-21","relationship":"same-class"},{"drugName":"sodium zirconium cyclosilicate","drugSlug":"sodium-zirconium-cyclosilicate","fdaApproval":"2018-05-18","patentExpiry":"Oct 22, 2033","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"sodium polystyrene sulfonate","indications":{"approved":[{"name":"Hyperkalemia","source":"DrugCentral","snomedId":14140009,"regulator":"FDA","eligibility":"Adults and pediatric patients with hyperkalemia"}],"offLabel":[],"pipeline":[]},"currentOwner":"Concordia","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"sevelamer","brandName":"sevelamer","genericName":"sevelamer","approvalYear":"1998","relationship":"same-class"},{"drugId":"lanthanum-carbonate","brandName":"lanthanum carbonate","genericName":"lanthanum carbonate","approvalYear":"2004","relationship":"same-class"},{"drugId":"sucroferric-oxyhydroxide","brandName":"sucroferric oxyhydroxide","genericName":"sucroferric oxyhydroxide","approvalYear":"2013","relationship":"same-class"},{"drugId":"calcium-acetate","brandName":"calcium acetate","genericName":"calcium acetate","approvalYear":"1982","relationship":"same-class"},{"drugId":"ferric-citrate","brandName":"ferric citrate","genericName":"ferric citrate","approvalYear":"2014","relationship":"same-class"},{"drugId":"patiromer-calcium","brandName":"patiromer calcium","genericName":"patiromer calcium","approvalYear":"2015","relationship":"same-class"},{"drugId":"sodium-zirconium-cyclosilicate","brandName":"sodium zirconium cyclosilicate","genericName":"sodium zirconium cyclosilicate","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03113981","phase":"NA","title":"Osseointegration of THA Grafted by PolyNASS (ACTISURF-CERAFIT® ) Versus Non-grafted THA (CERAFIT®)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Societe ACTIVBIOMAT","startDate":"2017-05-08","conditions":["Osteoarthritis, Hip","Coxarthrosis; Primary","Coxarthrosis; Secondary","Osteonecrosis; Aseptic, Idiopathic","Hip Arthroplasty Replacement","Hip Arthroplasty, Total","Hip Arthroplasty"],"enrollment":340,"completionDate":"2039-12"},{"nctId":"NCT04585542","phase":"PHASE4","title":"Comparison of Potassium Binders in the ER","status":"TERMINATED","sponsor":"University of California, Irvine","startDate":"2020-10-20","conditions":["Acute Hyperkalemia","Oral Potassium Binders"],"enrollment":37,"completionDate":"2025-01-31"},{"nctId":"NCT04789239","phase":"PHASE2","title":"OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Fu","startDate":"2021-09-01","conditions":["Heart Failure","Hyperkalemia"],"enrollment":110,"completionDate":"2025-12-31"},{"nctId":"NCT03305549","phase":"NA","title":"Recovery After Dialysis-Requiring Acute Kidney Injury","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2017-09-29","conditions":["Acute Kidney Injury"],"enrollment":16,"completionDate":"2019-11-13"},{"nctId":"NCT06029179","phase":"NA","title":"SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-01-15","conditions":["Hyperkalemia"],"enrollment":120,"completionDate":"2024-12-15"},{"nctId":"NCT06218212","phase":"NA","title":"The Effect of Renastart Formula Supplementation in Children With Acute Kidney Injury in Maintaining Normal Serum Electrolytes Levels","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-02-12","conditions":["Acute Kidney Injury"],"enrollment":24,"completionDate":"2023-06-30"},{"nctId":"NCT04566653","phase":"","title":"Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-10-23","conditions":["Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure"],"enrollment":147,"completionDate":"2022-01-12"},{"nctId":"NCT02065076","phase":"PHASE4","title":"Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients","status":"COMPLETED","sponsor":"Maisonneuve-Rosemont Hospital","startDate":"2014-02","conditions":["Hyperkalemia","Chronic Kidney Failure"],"enrollment":38,"completionDate":"2014-10"},{"nctId":"NCT01866709","phase":"PHASE4","title":"Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia","status":"TERMINATED","sponsor":"ZS Pharma, Inc.","startDate":"2013-05","conditions":["Hyperkalemia"],"enrollment":32,"completionDate":"2013-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Powder, Suspension","formulations":[{"form":"POWDER","route":"ORAL","productName":"Sodium Polystyrene Sulfonate"},{"form":"POWDER, FOR SUSPENSION","route":"ORAL","productName":"SODIUM POLYSTYRENE SULFONATE"},{"form":"POWDER, FOR SUSPENSION","route":"ORAL","productName":"Sodium Polystyrene Sulfonate"},{"form":"SUSPENSION","route":"ORAL","productName":"Sodium Polystyrene Sulfonate"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"1125","NDDF":"000753","UNII":"1699G8679Z","CHEBI":"CHEBI:53279","VANDF":"4018241","INN_ID":"8324","RXNORM":"1546437","UMLSCUI":"C0142915","chemblId":"CHEMBL1201484","ChEMBL_ID":"CHEMBL1201484","KEGG_DRUG":"D03263","DRUGBANK_ID":"DB01344","PUBCHEM_CID":"58817179","SNOMEDCT_US":"1002242008","SECONDARY_CAS_RN":"28210-41-5","MESH_SUPPLEMENTAL_RECORD_UI":"C003321"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1958-","companyName":"Concordia Pharms Inc","relationship":"Original Developer"},{"period":"present","companyName":"Concordia","relationship":"Current Owner"}],"publicationCount":420,"therapeuticAreas":["Gastroenterology"],"atcClassification":{"source":"DrugCentral","atcCode":"V03AE01","allCodes":["V03AE01"]},"biosimilarFilings":[],"originalDeveloper":"Concordia Pharms Inc","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":14,"_genericFilersChecked":true,"genericManufacturerList":["Ajenat Pharms","Ani Pharms","Chartwell Rx","Citrusphrma","Cmp Pharma Inc","Epic Pharma Llc","Hikma","Kvk Tech","Lyne","Morton Grove","Nuvo Pharms Inc","Pai Holdings Pharm","Roxane","Upsher Smith Labs"],"status":"approved","companyName":"Concordia","companyId":"concordia","modality":"Small molecule","firstApprovalDate":"1958","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1958-06-05T00:00:00.000Z","mah":"CONCORDIA PHARMS INC","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1991-12-04T00:00:00.000Z","mah":"CMP PHARMA INC","brand_name_local":null,"application_number":"ANDA089910"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2009-03-30T00:00:00.000Z","mah":"KVK TECH","brand_name_local":null,"application_number":"ANDA040905"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-03-03T00:00:00.000Z","mah":"CMP PHARMA INC","brand_name_local":null,"application_number":"ANDA087859"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-03-19T00:00:00.000Z","mah":"EPIC PHARMA LLC","brand_name_local":null,"application_number":"ANDA202333"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-05-03T00:00:00.000Z","mah":"ANI PHARMS","brand_name_local":null,"application_number":"ANDA040028"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:24:01.904489+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}